表观遗传DNA甲基化和组蛋白修饰在DLBCL中的研究进展
Advances of Epigenetic DNA Methylation and Histone Modifications in DLBCL
DOI: 10.12677/ACM.2024.141238, PDF,   
作者: 木提拜尔·米吉提：新疆医科大学研究生学院，新疆 乌鲁木齐；李 燕*：新疆维吾尔自治区人民医院血液科，新疆 乌鲁木齐
关键词: 弥漫大B细胞淋巴瘤；表观遗传学；DNA甲基化；组蛋白修饰；治疗；Diffuse Large B-Cell Lymphoma； Epigenetics； DNA Methylation； Histone Modification； Treatment
摘要: 弥漫性大B细胞淋巴瘤是一种常见的、具有侵袭性的造血系统恶性肿瘤，由于其异质性，具有不同的临床和病理特征。虽然目前的免疫化疗方案改善了临床结果，但仍有许多患者预后较差，复发频繁。表观遗传学的改变促进DLBCL的进展，其中DNA甲基化、组蛋白修饰等表观遗传学机制在基因的转录、表达及细胞的增殖、凋亡等过程中发挥至关重要的作用。随着DNA甲基转移酶抑制剂、组蛋白去乙酰化酶抑制剂等表观遗传药物的深入研究和临床应用，可以提高当前治疗疗效，改善DLBCL患者的预后。研究靶向的表观遗传机制可能是未来研究的关键。因此，本文主要就DLBCL的DNA甲基化和组蛋白修饰调控及其靶向治疗的研究进展进行综述。
Abstract: Diffuse large B-cell lymphoma is a common, aggressive hematopoietic malignancy with different clinical and pathological features due to its heterogeneity. Although current immunochemotherapy regimens have improved clinical outcomes, many patients still have poor prognosis and frequent relapses. Epigenetic changes promote the progression of DLBCL, in which epigenetic mechanisms such as DNA methylation and histone modification play a crucial role in gene transcription, expres-sion, and cell proliferation and apoptosis. With the intensive study and clinical application of epi-genetic drugs such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, it can improve the current therapeutic efficacy and improve the prognosis of patients with DLBCL. Re-search on the targeting epigenetic mechanisms may be critical for future research. Therefore, this paper mainly reviews the research progress of DNA methylation and histone modification regula-tion in DLBCL and its targeted therapy.
文章引用：木提拜尔·米吉提, 李燕. 表观遗传DNA甲基化和组蛋白修饰在DLBCL中的研究进展[J]. 临床医学进展, 2024, 14(1): 1658-1664. https://doi.org/10.12677/ACM.2024.141238

参考文献

[1] Chapuy, B., Stewart, C., Dunford, A.J., et al. (2018) Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Asso-ciated with Distinct Pathogenic Mechanisms and Outcomes. Nature Medicine, 24, 679-690.
[2] Sun, L., Zhang, H. and Gao, P. (2021) Metabolic Reprogramming and Epigenetic Modifications on the Path to Cancer. Protein & Cell, 13, 877-919. [Google Scholar] [CrossRef] [PubMed]
[3] Esteller, M. (2008) Epigenetics in Cancer. The New England Journal of Medicine, 358, 1148-1159. [Google Scholar] [CrossRef] 
[4] Lee, J.E. and Kim, M.Y. (2021) Cancer Epigenetics: Past, Present and Future. Seminars in Cancer Biology, 83, 4-14. [Google Scholar] [CrossRef] [PubMed]
[5] Frazzi, R., Zanetti, E., Pistoni, M., et al. (2017) Methylation Changes of SIRT1, KLF4, DAPK1 and SPG20 in B-Lymphocytes Derived from Follicular and Diffuse Large B-Cell Lymphoma. Leukemia Research, 57, 89-96. [Google Scholar] [CrossRef] [PubMed]
[6] Frazzi, R., Cusenza, V.Y., Pistoni, M., et al. (2022) KLF4, DAPK1 and SPG20 Promoter Methylation Is Not Affected by DNMT1 Silencing and Hypomethylating Drugs in Lym-phoma Cells. Oncology Reports, 47, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[7] Özdemir, İ., Pınarlı, F.G., Pınarlı, F.A., et al. (2018) Epigenetic Silenc-ing of the Tumor Suppressor Genes SPI1, PRDX2, KLF4, DLEC1, and DAPK1 in Childhood and Adolescent Lym-phomas. Pediatric Hematology and Oncology, 35, 131-144. [Google Scholar] [CrossRef] [PubMed]
[8] Cao, B., Guo, X., Huang, L., et al. (2021) Methylation Si-lencing CDH23 Is a Poor Prognostic Marker in Diffuse Large B-Cell Lymphoma. Aging, 13, 17768-17788. [Google Scholar] [CrossRef] [PubMed]
[9] Giesen, D., Hooge, M.N.L., Nijland, M., et al. (2022) 89Zr-PET Imag-ing to Predict Tumor Uptake of 177Lu-NNV003 Anti-CD37 Radioimmunotherapy in Mouse Models of B Cell Lympho-ma. Scientific Reports, 12, Article No. 6286. [Google Scholar] [CrossRef] [PubMed]
[10] Elfrink, S., Ter Beest, M., Janssen, L., et al. (2022) IRF8 Is a Transcriptional Activator of CD37 Expression in Diffuse Large B-Cell Lymphoma. Blood Advances, 6, 2254-2266. [Google Scholar] [CrossRef] [PubMed]
[11] Wedge, E., Hansen, J.W., Garde, C., et al. (2017) Global Hypomethylation Is an Independent Prognostic Factor in Diffuse Large B Cell Lymphoma. American Journal of Hema-tology, 92, 689-694. [Google Scholar] [CrossRef] [PubMed]
[12] Sun, X.J., Chen, Z. and Chen, S.J. (2019) Mutations in DNA Methyltransferases and Demethylases. In: Boffetta, P. and Hainaut, P., Eds., Encyclopedia of Cancer, Academic Press, Cambridge, 528-537.
[13] Duy, C., Béguelin, W. and Melnick, A. (2020) Epigenetic Mechanisms in Leukemias and Lymphomas. Cold Spring Harbor Perspectives in Medicine, 10, a034959. [Google Scholar] [CrossRef] [PubMed]
[14] Dominguez, P.M., Ghamlouch, H., Rosikiewicz, W., et al. (2018) TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-Cell Lym-phomagenesis. Cancer Discovery, 8, 1632-1653. [Google Scholar] [CrossRef] 
[15] Jiao, J., Lv, Z., Zhang, P., et al. (2020) AID Assists DNMT1 to Attenuate BCL6 Expression through DNA Methylation in Diffuse Large B-Cell Lymphoma Cell Lines. Neoplasia, 22, 142-153. [Google Scholar] [CrossRef] [PubMed]
[16] Nieto, Y., Valdez, B.C., Thall, P.F., et al. (2016) Double Epigenetic Modulation of High-Dose Chemotherapy with Azacitidine and vorinostat for Patients with Refractory or Poor-Risk Relapsed Lymphoma. Cancer, 122, 2680-2688. [Google Scholar] [CrossRef] [PubMed]
[17] Deng, Y., Chen, X., Huang, C., et al. (2019) EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-Cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions. Journal of Cancer, 10, 2006-2017. [Google Scholar] [CrossRef] [PubMed]
[18] Zhou, Y., Wang, X., An, Y.H., et al. (2020) Mechanism of Sorafenib and Decitabine Inducing Apoptosis of Diffuse Large B-Cell Lymphoma Cells. Journal of Experimental Hematology, 28, 146-152.
[19] Kwon, M., Park, K., Hyun, K., et al. (2020) H2B Ubiquityla-tion Enhances H3K4 Methylation Activities of Human KMT2 Family Complexes. Nucleic Acids Research, 48, 5442-5456. [Google Scholar] [CrossRef] [PubMed]
[20] Ortega-Molina, A., Boss, I.W., Canela, A., et al. (2015) The Histone Lysine Methyltransferase KMT2D Sustains a Gene Expression Program That Represses B Cell Lymphoma De-velopment. Nature Medicine, 21, 1199-1208. [Google Scholar] [CrossRef] [PubMed]
[21] Persky, D.O., Li, H., Rimsza, L.M., et al. (2018) A Phase I/II Trial of Vori-nostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. American Journal of Hematology, 93, 486-493. [Google Scholar] [CrossRef] [PubMed]
[22] Patrizia, M., Brea, E.J., et al. (2018) Panobinostat Acts Synergistically with Ibrutinib in Diffuse Large B Cell Lymphoma Cells with MyD88 L265 Mutations. JCI Insight, 3, e125568. [Google Scholar] [CrossRef] [PubMed]
[23] Islam, P., Rizzieri, D., Lin, C., et al. (2021) Phase II Study of Sin-gle-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Cancer Investigation, 39, 871-879. [Google Scholar] [CrossRef] [PubMed]
[24] Zhang, H., Chi, F., Qin, K., et al. (2021) Chidamide Induces Apoptosis in DLBCL Cells by Suppressing the HDACs/STAT3/Bcl2 Pathway. Molecular Medicine Reports, 23, Article No. 308. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, L., Qin, W., Huo, Y.J., et al. (2020) Advances in Targeted Therapy for Malignant Lymphoma. Signal Transduction and Targeted Therapy, 5, Article No. 15. [Google Scholar] [CrossRef] [PubMed]
[26] Gulati, N., Béguelin, W. and Giulino-Roth, L. (2018) Enhancer of Zeste Homolog 2 (EZH2) Inhibitors. Leukemia & Lymphoma, 59, 1574-1585. [Google Scholar] [CrossRef] [PubMed]
[27] Italiano, A., Soria, J.C., Toulmonde, M., et al. (2018) Taze-metostat, an EZH2 Inhibitor, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Advanced Solid Tumours: A First-in-Human, Open-Label, Phase 1 Study. The Lancet Oncology, 19, 649-659. [Google Scholar] [CrossRef] 
[28] Alderuccio, J.P. and Sharman, J.P. (2022) ABCs of ADCs in Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood Reviews, 56, Article ID: 100967. [Google Scholar] [CrossRef] [PubMed]
[29] Yap, T.A., Winter, J.N., Giulino-Roth, L., et al. (2019) Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hemato-logic and Solid Tumors. Clinical Cancer Research, 25, 7331-7339. [Google Scholar] [CrossRef] 
[30] Mei, H., Wu, H., Yang, J., et al. (2023) Discovery of IHMT-337 as a Potent Irreversible EZH2 Inhibitor Targeting CDK4 Transcription for Malignancies. Signal Transduction and Targeted Therapy, 8, Article No. 18. [Google Scholar] [CrossRef] [PubMed]

为你推荐